Updates are available Correction dated 2022-11-15
Click to view Correction: https://doi.org/10.1038/s41586-022-05548-6
-
Authors
Kalbasi, Anusha https://orcid.org/0000-0001-8692-1457
Siurala, Mikko
Su, Leon L. https://orcid.org/0000-0001-7654-9997
Tariveranmoshabad, Mito
Picton, Lora K. https://orcid.org/0000-0002-0482-5187
Ravikumar, Pranali
Li, Peng https://orcid.org/0000-0002-4721-5936
Lin, Jian-Xin
Escuin-Ordinas, Helena
Da, Tong
Kremer, Sarah V. https://orcid.org/0000-0001-9563-4986
Sun, Amy L.
Castelli, Sofia https://orcid.org/0000-0001-6185-2838
Agarwal, Sangya https://orcid.org/0000-0003-4272-515X
Scholler, John
Song, Decheng
Rommel, Philipp C. https://orcid.org/0000-0002-9790-4086
Radaelli, Enrico https://orcid.org/0000-0002-2885-0221
Young, Regina M.
Leonard, Warren J. https://orcid.org/0000-0002-5740-7448
Ribas, Antoni https://orcid.org/0000-0003-3669-8458
June, Carl H. https://orcid.org/0000-0003-0241-3557
Garcia, K. Christopher https://orcid.org/0000-0001-9273-0278
- License Information
-
More Information
Article History
Received: 20 March 2021
Accepted: 25 April 2022
First Online: 8 June 2022
Change Date: 15 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-022-05548-6
Competing interests
: A.K. serves on the advisory board of T-Cure Therapeutics and Certis Oncology, holds stock in Certis Oncology, and receives research funding from Highlight Therapeutics. K.C.G., L.L.S., and L.K.P. are inventors on patent application PCT/US2020/050232 on the ortho-9 technology and are shareholders in Synthekine Therapeutics. K.C.G. is the founder of Synthekine Therapeutics. A.R. has received honoraria for consulting with Amgen, Bristol-Myers Squibb, Chugai, Genentech, Merck, Novartis, Roche and Sanofi, is or has been a member of the scientific advisory board and holds stock in Advaxis, Arcus Biosciences, Highlight Therapeutics, Compugen, CytomX, Five Prime, FLX Bio, ImaginAb, IsoPlexis, Gilead Kite, Lutris Pharma, Merus, PACT Pharma, Rgenix and Tango Therapeutics. C.H.J. has received honoraria for consulting with, is a member of the board of directors for AC Immune, is a member of the scientific advisory board and holds stock in Bluesphere Bio, Cabaletta Bio, Carisma Therapeutics, Cellares, Celldex, DeCART Therapeutics, Kiadis Pharma, Tmunity Therapeutics, WIRB-Copernicus Group and Ziopharm Oncology, and receives royalties for intellectual property licensed to Novartis and Tmunity.
